Cellectis S.A.
CLLSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of. The $98.7M market capitalization puts CLLS squarely in micro-cap range for its industry. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Market Cap
$98.7M
Beta
2.91
P/E (TTM)
—
P/E (Fwd)
-1.58
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.62
ROE
-94.5%
ROA
-11.7%
Cash
$166.7M
Total Debt
$80.3M
Free CF
$107.7M
52W Change
-71.8%
Annual Financials
Cash vs Debt
Where CLLS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLLS finished 68.79% below its 150-day moving average ($2.98) and 71.12% below its 200-day moving average ($3.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLLS overbought or oversold?
At the October 20, 2026 close, CLLS's RSI(14) was 13.4, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $166.7M in cash comfortably exceeding the $80.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $107.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -94.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $19.2M (2022) to $72.9M (2025), reflecting a 281% increase over the period.
With a beta above 1.5, CLLS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing CLLS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.